Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation.

Shahar Shelly,Grayson Beecher,Margherita Milone,Teerin Liewluck,Floranne Ernste,James Triplett,Elie Naddaf,Anastasia Zekeridou,Andrew McKeon,Sean J Pittock,Divyanshu Dubey,John R Mills,Jay Mandrekar,Christopher J Klein

Rheumatology (Oxford, England)（2022）

引用 4|浏览6

暂无评分

摘要

Greater cancer risk is not observed in IMNM vs controls. Cancer screening in IMNM should be individualized based on age-personal and family history, including consideration of FDG-PET/CT. Immune-treatment response did not differ with cancer.

查看译文

关键词

HMGCR,SRP54,cancer,myopathy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要